Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation

Figure 1 Computed tomography and magnetic resonance imaging scans show that, compared to the baseline (A and E), the patient’s peritoneal effusion decreased after 3 cycles of chemotherapy treatment (B and F), tumor shrank after everlimus treatment for 2 mo (C and G), and stable disease was achieved after everlimus treatment for 4 mo (D and H).